Bank Julius Baer & Co
BMRN icon

Bank Julius Baer & Co’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bank Julius Baer & Co’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,397
Closed -$169K – 614
2025
Q1 		$169K Buy
+2,397
New +$161K ﹤0.01% 437
2024
Q2 		– Sell
-5,690
Closed -$497K – 496
2024
Q1 		$497K Sell
5,690
-19,890
-78% -$1.78M ﹤0.01% 317
2023
Q4 		$2.35M Buy
25,580
+11,405
+80% +$1.01M 0.01% 234
2023
Q3 		$1.25M Buy
14,175
+9,176
+184% +$816K 0.01% 243
2023
Q2 		$433K Sell
4,999
-2,224
-31% -$209K ﹤0.01% 349
2023
Q1 		$702K Sell
7,223
-2,415
-25% -$250K ﹤0.01% 310
2022
Q4 		$997K Sell
9,638
-2,247
-19% -$211K 0.01% 267
2022
Q3 		$1.01M Buy
11,885
+4,807
+68% +$428K 0.01% 253
2022
Q2 		$587K Sell
7,078
-515
-7% -$41K ﹤0.01% 330
2022
Q1 		$585K Buy
7,593
+2,180
+40% +$182K ﹤0.01% 333
2021
Q4 		$478K Sell
5,413
-2,137
-28% -$176K ﹤0.01% 426
2021
Q3 		$584K Sell
7,550
-1,654
-18% -$131K ﹤0.01% 409
2021
Q2 		$768K Buy
9,204
+1,946
+27% +$154K ﹤0.01% 384
2021
Q1 		$548K Sell
7,258
-6,791
-48% -$555K ﹤0.01% 430
2020
Q4 		$1.23M Buy
14,049
+6,748
+92% +$535K 0.01% 317
2020
Q3 		$55K Buy
7,301
+591
+9% +$59.8K ﹤0.01% 597
2020
Q2 		$828K Buy
6,710
+2,219
+49% +$221K 0.01% 298
2020
Q1 		$379K Buy
+4,491
New +$387K 0.01% 343

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank Julius Baer & Co's BMRN Position: Q2 2025 in Review

Bank Julius Baer & Co sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2025, closing a stake of 2,397 shares — an estimated $169K sold.

Bank Julius Baer & Co first reported a position in BMRN in Q1 2020 and held it in 18 quarters. The position peaked at $2.35M in Q4 2023. 581 funds tracked by Wall St. Rank hold BMRN as of Q2 2025.

  • Bank Julius Baer & Co reported no remaining BioMarin Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Bank Julius Baer & Co sold 2,397 BioMarin Pharmaceuticals shares in Q2 2025, an estimated $169K.
  • Bank Julius Baer & Co first reported a position in BioMarin Pharmaceuticals in Q1 2020 and held it in 18 quarters.
  • Bank Julius Baer & Co's BioMarin Pharmaceuticals position peaked at $2.35M in Q4 2023.
  • 581 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2025.

Based on Bank Julius Baer & Co's 13F filing for Q2 2025, filed 12 Aug 2025.